Biotech company Biogen lowered its full-year profit forecast, citing higher costs related to its purchase of drug maker Reata Pharmaceuticals as well as the launch of its Alzheimer's drug.

Share:
More In Business
The Fed Decides to Hold Rates Steady
Brad Bernstein, managing director at UBS Private Wealth Management breaks down the state of the U.S. economy and what to expect from Fed policy from the rest of the year.
Load More